The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Real-world treatment patterns in third-line patients with metastatic renal cell carcinoma (mRCC): The changing landscape in the United States.
Sumanta Kumar Pal
Consultant or Advisory Role - Novartis; Novartis; Novartis
Honoraria - Novartis; Novartis; Novartis
Elisabetta Malangone
Employment or Leadership Position - LA-SER Analytica; LA-SER Analytica; LA-SER Analytica
Consultant or Advisory Role - LA-SER Analytica; LA-SER Analytica; LA-SER Analytica
Sharvari Bhurke
Employment or Leadership Position - LA-SER Analytica; LA-SER Analytica; LA-SER Analytica
Consultant or Advisory Role - LA-SER Analytica; LA-SER Analytica; LA-SER Analytica
Magdaliz Gorritz
Employment or Leadership Position - LA-SER Analytica; LA-SER Analytica; LA-SER Analytica
Consultant or Advisory Role - LA-SER Analytica; LA-SER Analytica; LA-SER Analytica
Lee Stern
Employment or Leadership Position - LA-SER Analytica
Research Funding - LA-SER Analytica; LA-SER Analytica received funding for this research from Novartis; LA-SER Analytica received funding for this research from Novartis; Novartis
John Coombs
Employment or Leadership Position - Novartis; Novartis; Novartis
Stock Ownership - Novartis; Novartis; Novartis
James D. Turnbull
Employment or Leadership Position - Novartis; Novartis
Xufang Wang
Employment or Leadership Position - Novartis; Novartis
Stock Ownership - Novartis; Novartis; Novartis
Zhimei Liu
Employment or Leadership Position - Novartis; Novartis
Stock Ownership - Novartis; Novartis